Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Products were manufactured in a processing area in which water leakage was observed
| Brand name | GABAPENTIN |
| Generic name | GABAPENTIN |
| Active ingredient(s) | GABAPENTIN |
| Distributed by / for | Aurobindo Pharma USA, Inc. Dayton, NJ 08810 |
| NDC | 65862-198-99 |
| Full product label | Gabapentin Capsules, USP 100mg 1,000-count bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810, NDC 65862-198-99 |
| Recalling firm | Aurobindo Pharma USA Inc. |
| Distribution | Nationwide within the United States |
| Quantity | 26625 units |
| Recall initiated | 2020-03-18 |
| Report date | 2020-04-22 |
| Recall completed | 2024-03-25 |
| Recall number | D-1232-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | East Windsor NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗